Editorial
Primum non nocere
First published: 15 July 2015
No abstract is available for this article.
References
- 1Lakos A, Igari Z, Solymosi N. Recent lesson from a clinical and seroepidemiological survey: low positive predictive value of Borrelia burgdorferi antibody testing in a high risk population. Adv Med Sci 2012; 57: 356–363.
- 2Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85–92.
- 3Krupp LB, Hyman LG, Grimson R. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60: 1923–1930.
- 4Dersch R, Freitag M, Schmidt St, Sommer H, Rauer S, Meerpohl J. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis – a systematic review. Eur J Neurol 2015; 22: 1421–1428.
- 5Mygland A1, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS-guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010; 17: 8–16.
- 6Bauer MP, Notermans DW, van Benthem BH; ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63–73.
- 7Sabau L1, Meybeck A, Gois J. Clostridium difficile colitis acquired in the intensive care unit: outcome and prognostic factors. Infection 2014; 42: 23–30.
- 8 European Centre for Disease Prevention and Control. Annual Epidemiological Report 2014. Antimicrobial Resistance and Healthcare-Associated Infections. ECDC: Stockholm, 2015.
